2020.08.13 – Advances in Traumatic Brain Injury Evaluation and Management (Recorded Webinar)

A Robert Sbordone Memorial mTBI/Concussion Lecture recorded webinar featuring Jeff Bazarian, M.D., M.P.H., and Robert D. Welch, M.D., M.S.

If you select "Add to Basket" below, you will be prompted to continue to payment. When you have completed the checkout process, you will receive an email with further instructions. The file contained in this email also includes instructions for receiving your ACBIS CEU.

Select this box to receive helpful information from Abbott Laboratories in the future.

*To read the full opt-in disclaimer, scroll down.

 Aired live August 13, 2020. Includes 1 ACBIS CEU.

Worldwide each year, 50 million+ people sustain a traumatic brain injury (TBI); most cases are mild with variable clinical outcomes and lasting symptoms (Nelson, 2019). However, due to limitations of current evaluation tools, it is challenging to adequately assess injury severity, predict outcomes, and determine optimal treatment to improve outcomes.

Hear from leading experts about effective strategies and trends related to brain injury evaluation, the latest blood-based biomarker research, and their potential to predict the absence of intracranial injury. Two proteins, Ubiquitin C-terminal hydrolase-L1 (UCH-L1) and Glial fibrillary acidic protein (GFAP), have emerged as promising biomarkers for clinical use in an acute care setting to predict traumatic intracranial injuries on head CT scan after TBI. These biomarkers have the potential to reduce unnecessary head CT scanning in detecting TBI, improve patient care, and operational efficiency such as length of stay and patient satisfaction..

In this webinar, Jeff Bazarian, M.D., M.P.H., and Robert D. Welch, M.D., M.S., discuss how biomarkers may be used in the future clinically to improve patient care in the hospital and outpatient setting. They will also identify the role of brain biomarkers in hospital performance.

Learning Objectives:

  • Describe unmet needs and challenges regarding the current tools and approach to traumatic brain injury evaluation
  • Examine how the current approach to TBI evaluation impacts patient care and burden to the hospital
  • Highlight developments regarding the use of biomarkers for TBI evaluation
  • Discuss the ways in which biomarkers may be used in the future clinically to improve patient care in the hospital and outpatient care setting
  • Assess the role of brain biomarker tests in the hospital performance

Speaker Bios:

Jeff Bazarian is a Professor of Emergency Medicine and Neurology at the University of Rochester. He is a graduate of Brown University and the University of Rochester School of Medicine and Dentistry. He is board-certified in Internal Medicine and Emergency Medicine but practiced Emergency Medicine exclusively for 22 years until 2012. In 2010, Dr. Bazarian joined the University of Rochester Sports Concussion Clinic, providing outpatient concussion care to area high school and collegiate athletes. Dr. Bazarian’s research is focused on developing neuroimaging and blood-based biomarkers of axonal injury after concussion and repetitive head hits, and the pathophysiologic mechanisms of recovery. He, along with Dr. Welch, were lead authors on the 2018 Lancet Neurology publication detailing the results of the multi-national ALERT-TBI trial used to support FDA clearance of the first test to use blood-based biomarkers of traumatic brain injury in the US.

Robert D. Welch is a Professor and Clinical Educator in the Department of Emergency Medicine and is the Director of the Biostatistics and Epidemiology Research Design Group. He is a member of the Cardiovascular Research Institute and an Associate in the Department of Physical Medicine and Rehabilitation at Wayne State University School of Medicine in Detroit, Michigan. Robert Welch completed his M.D. degree at Wayne State University School of Medicine, his residency in Emergency Medicine at Detroit Receiving Hospital/Wayne State University, and an M.S. in Clinical Research Design and Statistical Analysis at the University of Michigan. Rob’s interests include neurological emergencies, clinical trials methodology, and heart disease. He was the Program Director of the Wayne State University Neurological Emergencies Treatment Trials Network from 2007 – 2018 and held numerous clinical research contracts with foundations and industry.


Nelson LD, Temkin NR, Dikmen S, et al. Recovery After Mild Traumatic Brain Injury in Patients Presenting to US Level I Trauma CentersA Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) StudyJAMA Neurol. 2019;76(9):1049–1059. doi:10.1001/jamaneurol.2019.1313



By selecting yes above, I agree that my information will be shared with webinar partner Abbott and that: (1) the information I've provided will be used only by Abbott Point of Care, its affiliates, and contracted third parties to mail, telephone, and email me helpful information on products and services, and for marketing and information purposes, (2) Abbott Point of Care will not sell or transfer my name or contact information to any third party for its marketing use, (3) I may be removed from Abbott Point of Care’s mailing list or request a copy of this information by contacting 1-609-454-9000. In the event this form is incomplete or filled out incorrectly, Abbott Point of Care may contact you for further clarification, (4) Abbott Point of Care stores my personal information securely and in accordance with applicable laws and standards, (5) Abbott Point of Care may transmit my personal information to other Abbott locations worldwide, including other countries that may not have the same data protection requirements as my country. However, Abbott Point of Care and all its affiliates and locations worldwide are required to protect and treat my personal information in a manner consistent with this notice and in accordance with Abbott Point of Care’s policies and applicable laws. For further information about Abbott’s privacy policy, please read the applicable privacy policy for your country.